$142 Million is the total value of MWG Management Ltd.'s 3 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BEAM | BEAM THERAPEUTICS INC | $71,863,119 | -21.7% | 2,346,934 | 0.0% | 50.60% | +8.0% | |
| LYEL | LYELL IMMUNOPHARMA INC | $47,583,104 | -32.0% | 20,162,332 | 0.0% | 33.50% | -6.2% | |
| PRIME MEDICINE INC | $22,581,275 | -33.8% | 1,835,876 | 0.0% | 15.90% | -8.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Milky Way Investments Group Ltd. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BEAM THERAPEUTICS INC | 12 | Q3 2023 | 94.5% |
| LYELL IMMUNOPHARMA INC | 10 | Q3 2023 | 59.1% |
| PRIME MEDICINE INC | 4 | Q3 2023 | 17.4% |
| VIR BIOTECHNOLOGY INC | 3 | Q2 2021 | 8.1% |
| RELX PLC | 2 | Q3 2021 | 37.3% |
| Illumina Inc | 1 | Q3 2021 | 16.6% |
View MWG Management Ltd.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-02-14 |
View MWG Management Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.